About Dr. Andrej Jedinak

Scientist. Strategist. Consultant. Bridging the gap between discovery science and clinical impact.

Dr. Andrej Jedinak, PhD
🎓 Harvard Medical School
🎓 Indiana University
🔬 PhD, Biotechnology

Andrej Jedinak, PhD

Drug Discovery Consultant & Scientific Advisor

Dr. Andrej Jedinak is a highly accomplished drug discovery and development scientist with over two decades of experience spanning academic research and the biopharmaceutical industry. His career reflects a deep commitment to translating fundamental science into novel therapeutic strategies.

"My goal is to help organizations navigate the complexity of drug discovery with the clarity that comes from both deep scientific expertise and practical industry experience."

Following postdoctoral training at Boston Children's Hospital / Harvard Medical School and the Methodist Research Institute at Indiana University, Dr. Jedinak built an impressive track record in the biotech and pharmaceutical sectors. He has held key scientific roles at companies including Phio Pharmaceuticals, Agenus Inc., and Pledge Therapeutics, contributing to programs spanning immunology, oncology, and metabolic diseases.

His expertise encompasses the full drug discovery continuum — from target identification and validation through preclinical development, with particular strength in in vitro, ex vivo, and in vivo pharmacology. Dr. Jedinak has extensive hands-on experience with diverse therapeutic modalities including small molecules, biologics, antibodies, RNAi constructs, and gene therapy approaches.

Today, Through this consulting practice, he provides strategic and scientific consulting to biotech and pharmaceutical organizations seeking to advance their drug discovery pipelines with the same rigor and creativity that has defined his career.

Areas of Expertise

Comprehensive scientific knowledge spanning multiple therapeutic domains and drug modalities.

🧬

Therapeutic Areas

  • Immunology & Autoimmune Diseases (RA, IBD, Psoriasis, Lupus, MS)
  • Oncology & Immuno-Oncology (solid tumors, hematologic malignancies)
  • Rare & Metabolic Diseases (Gaucher, Fabry, Niemann-Pick, NASH)
  • Inflammatory diseases and cytokine biology
  • Tumor microenvironment and checkpoint inhibition
  • Orphan diseases and rare pediatric conditions
⚗️

Drug Modalities

  • Small molecule inhibitors and activators
  • Biologics (monoclonal antibodies, fusion proteins)
  • RNAi therapeutics (siRNA, shRNA, microRNA)
  • Gene therapy and gene editing approaches
  • Antisense oligonucleotides (ASOs)
  • Cell therapies and immune cell modulation
  • Enzyme replacement and substrate reduction therapy
🔬

Pharmacology & Biology

  • In vitro pharmacology — cell-based assays, biochemical assays
  • Ex vivo pharmacology — primary cell models, tissue explants
  • In vivo pharmacology — efficacy, PK/PD, mechanistic studies
  • Translational biomarker development
  • Disease model development and validation
  • Target identification using multi-omics approaches
📊

Strategy & Business

  • Research strategy and portfolio prioritization
  • Competitive intelligence and landscape analysis
  • Scientific advisory board support
  • Grant writing and scientific communication
  • Due diligence for biotech investments
  • CRO selection and vendor management

Career Timeline

A track record built across leading academic institutions and biopharmaceutical companies.

Current

Consultant / Scientific Advisor

Independent Consulting

Providing strategic and scientific consulting services to biotech and pharmaceutical organizations across drug discovery, pharmacology, and translational science.

Recent

Pledge Therapeutics

Associate Director / Preclinical Development

Led translational research strategies and biomarker discovery programs, integrating human clinical samples, molecular biology, and in vitro, ex vivo and in vivo models to advance mechanistic understanding of disease biology.

Previous

Agenus Inc.

Program Lead / Preclinical Development

Led immunology and oncology preclinical programs. Developed and validated in vitro and in vivo models advancing mechanistic understanding of immune checkpoint biology and antibody-based cancer immunotherapy.

Previous

Phio Pharmaceuticals Inc.

Principal Scientist / Preclinical Development

Designed and executed pharmacology programs for RNAi-based cancer immunotherapy candidates, with focus on immune cell engineering and tumor microenvironment modulation.

Postdoc

Boston Children's Hospital / Harvard Medical School

Postdoctoral Research Fellow

Led translational research strategies and biomarker discovery programs, integrating human clinical samples, molecular biology, and in vitro, ex vivo and in vivo models to advance mechanistic understanding of disease biology.

Postdoc

Methodist Research Institute, Indiana University

Postdoctoral Research Fellow

Investigated molecular mechanisms of cancer and inflammation, establishing foundational expertise in cell biology, biochemistry, and in vivo disease model systems.

Let's Work Together

Ready to bring deep scientific expertise to your drug discovery program? Let's connect and explore how we can accelerate your pipeline.